Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis

被引:18
作者
vanderPijl, JW
Srivastava, N
Denouel, J
Burggraaf, J
Schoemaker, RC
vanderWoude, FJ
Cohen, AF
机构
[1] CTR HUMAN DRUG RES, NL-2333 CL LEIDEN, NETHERLANDS
[2] LABS SANDOZ, CTR RECH PHARMACEUT, UNITE PHARMACOCINET, F-92506 RUEIL MALMAISON, FRANCE
关键词
D O I
10.1097/00007890-199608270-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cyclosporine (CsA) is an immunosuppressive drug requiring dose individualization and regular control due to its highly variable pharmacokinetics. Since gastroparesis may influence the absorption of CsA, a randomized cross-over study was performed to assess the pharmacokinetics and tolerability of a novel microemulsion CsA formulation in comparison with the standard CsA dosage form in six stable pancreas-kidney transplant recipients with scintigraphically proven gastroparesis. The absorption of CsA was investigated during three 2-hr study days during each treatment period, and a full pharmacokinetic profile was done for each formulation. No adverse events or differences in tolerability/safety parameters between the treatments were found. The average AUC(0-->2 hp) was 150% higher after the novel formulation, The coefficient of variation in AUC(0-->2 hr) for both formulations was comparable (37% after the microemulsion and 40% after the standard formulation). The median time at which blood CsA levels exceeded the preceding trough level by 20% was 30 min (range: 29-182 min) after the microemulsion and 90 min (range: 30->718 min) after the standard formulation. With approximately the same average dose, the AUC(tau)(ss) after the microemulsion was 81% higher than the standard formulation, while predose and 12-hr trough levels were similar. The average maximal CsA plasma level after the microemulsion was 396 ng/ml (95%CI: 71-722 ng/ml) higher than after the standard formulation. The median time at which the highest blood levels were observed was 90 min (range: 62-208 min) after the microemulsion and 225 min (range: 150->718 min) after the standard formulation. The time profiles of the CsA metabolites followed those of the parent compound. The microemulsion resulted in a higher systemic exposure to CsA than the standard formulation in pancreas-kidney transplant patients with diabetic gastroparesis, but substantial variability in blood concentrations remained.
引用
收藏
页码:456 / 462
页数:7
相关论文
共 19 条
  • [1] BIRD NJ, 1994, NEPHROL DIAL TRANSPL, V9, P287
  • [2] BOONSTRA JG, 1995, J AM SOC NEPHROL, V5, P1918
  • [3] GASTROPARESIS OF DIGESTIBLE AND INDIGESTIBLE SOLIDS IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS OR FUNCTIONAL DYSPEPSIA
    CABALLEROPLASENCIA, AM
    MUROSNAVARRO, MC
    MARTINRUIZ, JL
    VALENZUELABARRANCO, M
    DELOSREYESGARCIA, MC
    VILCHEZJOYA, R
    CASADOCABALLERO, FJ
    GILEXTREMERA, B
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (07) : 1409 - 1415
  • [4] CYCLOSPORINE IN THERAPEUTIC DOSES INCREASES RENAL-ALLOGRAFT VASCULAR-RESISTANCE
    CURTIS, JJ
    DUBOVSKY, E
    WHELCHEL, JD
    LUKE, RG
    DIETHELM, AG
    JONES, P
    [J]. LANCET, 1986, 2 (8505) : 477 - 479
  • [5] THE ABSORPTION SITE OF CYCLOSPORINE IN THE HUMAN GASTROINTESTINAL-TRACT
    DREWE, J
    BEGLINGER, C
    KISSEL, T
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) : 39 - 43
  • [6] INVITRO IMMUNOSUPPRESSIVE PROPERTIES OF CYCLOSPORINE METABOLITES
    FREED, BM
    ROSANO, TG
    LEMPERT, N
    [J]. TRANSPLANTATION, 1987, 43 (01) : 123 - 127
  • [7] OPTIMIZATION OF IMMUNOSUPPRESSIVE THERAPY USING PHARMACOKINETIC PRINCIPLES
    GREVEL, J
    [J]. CLINICAL PHARMACOKINETICS, 1992, 23 (05) : 380 - 390
  • [8] HOLT DW, 1990, TRANSPLANT P, V22, P1234
  • [9] DISORDERED GASTRIC MOTOR FUNCTION IN DIABETES-MELLITUS
    HOROWITZ, M
    FRASER, R
    [J]. DIABETOLOGIA, 1994, 37 (06) : 543 - 551
  • [10] KAHAN BD, 1995, TRANSPLANTATION, V59, P505